AccurKardia

AccurKardia is a United States-based analytics startup founded in 2019. The company specializes in ECG-led diagnostics and aims to revolutionize the diagnostic coverage and disease management in cardiology and other related fields. The flagship product, AccurECG, is an FDA cleared (Class II SaMD) software intended to automate ECG interpretation and detect up to 13 arrhythmias. This innovative product is designed to facilitate the analysis of ECGs recorded from holters, event recorders, and cardiac telemetry devices, and has potential applications beyond cardiology. Moreover, the company has gained recognition by being accepted into the MedTech Innovator 2024 Cohort and the Heart and Brain Health Accelerator track in collaboration with the American Heart Association’s Center for Health Technology and Innovation. The latest investment received by AccurKardia was a Non Equity Assistance investment on 29 May 2024, with the investment coming from MedTech Innovator. This undoubtedly signals the investor's confidence in the potential of the company and its products. With its cutting-edge technology and substantial industry recognition, AccurKardia is well-positioned for growth and may have a significant impact on the future of diagnostics and disease management, both in cardiology and across other medical fields.